Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from The USFDA for Lubiprostone Capsules, 8 mcg and 24 mcg
Details : Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. It is indicated for chronic idiopathic constipation and IBS with const...
Product Name : Amitiza-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
March 24, 2023
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
